Efficacy and safety of subcutaneous immunotherapy with a mixture of glutaraldehyde-modified extracts of Dermatophagoides pteronyssinus, Dermatophagoides farinae , and Blomia tropicalis

Ricardo Cardona-Villa; Susana Uribe-Garcia; Víctor Daniel Calvo-Betancur; Jose Fernando Cantillo; Enrique Fernández-Caldas

doi:10.1016/j.waojou.2022.100692

Efficacy and safety of subcutaneous immunotherapy with a mixture of glutaraldehyde-modified extracts of Dermatophagoides pteronyssinus, Dermatophagoides farinae , and Blomia tropicalis

World Allergy Organ J. 2022 Sep 8;15(9):100692. doi: 10.1016/j.waojou.2022.100692. eCollection 2022 Sep.

Authors

Ricardo Cardona-Villa¹, Susana Uribe-Garcia¹, Víctor Daniel Calvo-Betancur¹, Jose Fernando Cantillo², Enrique Fernández-Caldas³

Affiliations

¹ Grupo de Alergología Clínica y Experimental (GACE), University of Antioquia, Medellín, Antioquia, Colombia.
² Inmunotek, S.L. Alcalá de Henares, Madrid, Spain.
³ Inmunotek, S.L. Madrid and University of South Florida College of Medicine, Tampa, FL, USA.

Abstract

Background: Allergen Immunotherapy (AIT) is an effective treatment of allergic respiratory diseases induced by the inhalation of house dust mite allergens.

Objectives: To evaluate the efficacy and safety of glutaraldehyde polymerized allergen extracts using a mixture of Dermatophagoides pteronyssinus, D. farinae and Blomia tropicalis in mite allergic individuals residing in Colombia.

Methods: Two hundred and fifty (250) patients with allergic rhinoconjunctivitis with, or without asthma and sensitized to D. pteronyssinus, D. farinae and B. tropicalis were included. A glutaraldehyde-modified extract containing a mixture of D. pteronyssinus, D. farinae and B. tropicalis was employed, using a cluster up-dosing schedule followed by a monthly maintenance dose. The primary endpoints to evaluate the clinical impact were the Combined Symptom and Medication Scores (CSMS) for allergic rhinitis, the Asthma Control Test (ACT) and the reduction in medication consumption.

Results: Significant improvement was found after 3 months of treatment regarding CSMS (p < 0.0001) and ACT (p < 0.0001). Additionally, a significant decrease in medication consumption was found after 3 months of treatment (p < 0.0001). Adverse reactions, either local or systemic were mild and no severe reactions related to the vaccines were observed.

Conclusion: After 12 months of allergen immunotherapy, glutaraldehyde-modified mixture of D. pteronyssinus, D. farinae and B. tropicalis proved to be safe and effective in the treatment of patients with rhinoconjunctivitis with or without asthma due to allergy to mites.

Keywords: Allergic rhino-conjunctivitis; Glutaraldehyde-polymerized extracts; House dust mites; Immunotherapy.